Effect of TACE combined with radiofrequency ablation on tumor related serum biomarker levels in patients with primary hepatocellular carcinoma
Objective To observe the effects of transarterial chemoembolization(TACE)combined with radiofrequency ablation(RFA)on tumor-associated serum biomarkers in patients with primary hepato-cellular carcinoma,aiming to provide a scientific reference for the treatment of related clinical diseases.Meth-ods Using a random number table method,78 patients with primary hepatocellular carcinoma treated from February 2019 to February 2021 were divided into the control group(39 patients,treated with TACE)and the combined group(39 patients,treated with TACE+RFA).The short-term efficacy,related serum biomarkers[serum E-cadherin(EC),alpha-fetoprotein(AFP),matrix metallopeptidase-9(MMP-9),vascular endothelial growth factor(VEGF),alanine aminotransferase(ALT),total bilirubin(TBIL),gamma-glutamyl transferase(GGT),and carbohydrate antigen 199(CA199)],and survival rates were compared between the two groups.Results The total effective rate of the combined group was significantly higher than that of the control group(P＜0.05).No significant difference was observed in disease control rates between the two groups(P＞0.05).At the end of the treatment,the expression levels of serum EC,VEGF,MMP-9,AFP,ALT,TBIL,CA199,and GGT decreased in both groups,with the combined group showing significantly lower levels than the control group(P＜0.05).There was no significant difference in the 6-month and 1-year survival rates be-tween the two groups(P＞0.05),but the 2-year survival rate was higher in the combined group,with a statis-tically significant difference(P＜0.05).Conclusion The combination of TACE and RFA in treating primary hepatocellular carcinoma is beneficial in improving short-term therapeutic effects,reducing serum tumor markers,and enhancing safety,and can increase the 2-year survival rate of patients.
Primary hepatocellular carcinomaHepatic artery chemoembolizationRadio frequency ablationTumor markers
万方数据
维普
